Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    CAR-TCR Global 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

CAR-T

Exciting advances in CAR-T and TCR research 2:49
Exciting advances in CAR-T and TCR research
David Gilham • 22 Feb 2021
DARIC33 CAR T-cells in AML 2:38
DARIC33 CAR T-cells in AML
Jacob Appelbaum • 12 May 2021
Identifying early predictors of neurotoxicity following CAR-T infusion 2:55
Identifying early predictors of neurotoxicity following CAR-T infusion
Jaap Boelens • 26 May 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
DARIC33: CAR T with an on/off switch 1:40
DARIC33: CAR T with an on/off switch
Jacob Appelbaum • 12 May 2021
What to expect at ISCT 2021 1:50
What to expect at ISCT 2021
Bruce Levine • 11 Mar 2021
Combining iNKT and CAR technology 6:34
Combining iNKT and CAR technology
Marc van Dijk • 23 Feb 2021
How the TCR field can learn from CARs 3:23
How the TCR field can learn from CARs
Dolores Schendel • 25 Feb 2021
Targetting cancer with allogeneic NK cell therapies 3:05
Targetting cancer with allogeneic NK cell therapies
James Trager • 10 Mar 2021
CAR-NKs for B cell malignancies 2:09
CAR-NKs for B cell malignancies
James Trager • 10 Mar 2021
CT053, anti-GPC3 CAR-T and targeting solid tumors 4:15
CT053, anti-GPC3 CAR-T and targeting solid tumors
Hong Ma • 19 Feb 2021
CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC 3:24
CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC
David Gilham • 22 Feb 2021
Analysing trends in the CAR-TCR landscape 3:28
Analysing trends in the CAR-TCR landscape
Vasiliki Zochiou • 22 Feb 2021
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS 2:29
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS
David Gilham • 22 Feb 2021
CAR-TCR Europe highlights: synthetic biology & the autologous vs allogeneic debate 1:48
CAR-TCR Europe highlights: synthetic biology & the autologous vs allogeneic debate
Dalip Sethi • 23 Feb 2021
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy